Akane Yamamichi, MD, PhD
Specialist
Neurological Surgery
School of Medicine

Publications (27)

Top publication keywords:
GlioblastomaHLA-A2 AntigenBrain NeoplasmsX-linked Nuclear ProteinGene ExpressionBiomarkers, TumorImmunotherapy, AdoptiveMicrobubblesEnhancer of Zeste Homolog 2 ProteinInterferon Regulatory FactorsTumor MicroenvironmentIsocitrate DehydrogenaseGliomaGene DeletionImmunohistochemistry

• Interferon regulatory factor 8-driven reprogramming of the immune microenvironment enhances antitumor adaptive immunity and reduces immunosuppression in murine glioblastoma.
  Neuro-oncology 2024 Montoya M, Collins SA, Chuntova P, Patel TS, Nejo T, Yamamichi A, Kasahara N, Okada H
• Ultrasound frequency-controlled microbubble dynamics in brain vessels regulate the enrichment of inflammatory pathways in the blood-brain barrier.
  Nature communications 2024 Guo Y, Lee H, Kim C, Park C, Yamamichi A, Chuntova P, Gallus M, Bernabeu MO, Okada H, Jo H, Arvanitis C
• Enhancing CAR-T cell metabolism to overcome hypoxic conditions in the brain tumor microenvironment.
  JCI insight 2024 Hatae R, Kyewalabye K, Yamamichi A, Chen T, Phyu S, Chuntova P, Nejo T, Levine LS, Spitzer MH, Okada H
• IRF8-driven reprogramming of the immune microenvironment enhances anti-tumor adaptive immunity and reduces immunosuppression in murine glioblastoma.
  bioRxiv : the preprint server for biology 2024 Montoya M, Collins SA, Chuntova P, Patel TS, Nejo T, Yamamichi A, Kasahara N, Okada H
• Challenges in the discovery of tumor-specific alternative splicing-derived cell-surface antigens in glioma.
  Scientific reports 2024 Nejo T, Wang L, Leung KK, Wang A, Lakshmanachetty S, Gallus M, Kwok DW, Hong C, Chen LH, Carrera DA, Zhang MY, Stevers NO, Maldonado GC, Yamamichi A, Watchmaker PB, Naik A, Shai A, Phillips JJ, Chang …

Show all (22 more) Hide

• Correction: Gallus et al. Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma. Cancers 2023, 15, 3726.
  Cancers 2023 Gallus M, Kwok D, Lakshmanachetty S, Yamamichi A, Okada H
• Enhancing CAR-T Cell Metabolism to Overcome Hypoxic Conditions in the Brain Tumor Microenvironment.
  bioRxiv : the preprint server for biology 2023 Hatae R, Kyewalabye K, Yamamichi A, Chen T, Phyu S, Chuntova P, Nejo T, Levine LS, Spitzer MH, Okada H
• Challenges in the discovery of tumor-specific alternative splicing-derived cell-surface antigens in glioma.
  bioRxiv : the preprint server for biology 2023 Nejo T, Wang L, Leung KK, Wang A, Lakshmanachetty S, Gallus M, Kwok DW, Hong C, Chen LH, Carrera DA, Zhang MY, Stevers NO, Maldonado GC, Yamamichi A, Watchmaker P, Naik A, Shai A, Phillips JJ, Chang …
• Tumor-wide RNA splicing aberrations generate immunogenic public neoantigens.
  bioRxiv : the preprint server for biology 2023 Kwok DW, Stevers NO, Nejo T, Chen LH, Etxeberria I, Jung J, Okada K, Cove MC, Lakshmanachetty S, Gallus M, Barpanda A, Hong C, Chan GKL, Wu SH, Ramos E, Yamamichi A, Liu J, Watchmaker P, Ogino H, …
• Glioma-neuronal circuit remodeling induces regional immunosuppression.
  bioRxiv : the preprint server for biology 2023 Nejo T, Krishna S, Jimenez C, Yamamichi A, Young JS, Lakshmanachetty S, Chen T, Phyu SSS, Ogino H, Watchmaker P, Diebold D, Choudhury A, Daniel AGS, Raleigh DR, Hervey-Jumper SL, Okada H
• Immunotherapy Approaches in Isocitrate-Dehydrogenase-Mutant Low-Grade Glioma.
  Cancers 2023 Gallus M, Kwok D, Lakshmanachetty S, Yamamichi A, Okada H
• Correspondence on 'H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2+ patients with diffuse midline glioma' by Immisch et al.
  Journal for immunotherapy of cancer 2023 Chheda ZS, Mueller S, Hegde B, Yamamichi A, Butterfield LH, Okada H
• Efficacy of cancer-specific anti-podoplanin CAR-T cells and oncolytic herpes virus G47Δ combination therapy against glioblastoma.
  Molecular therapy oncolytics 2022 Chalise L, Kato A, Ohno M, Maeda S, Yamamichi A, Kuramitsu S, Shiina S, Takahashi H, Ozone S, Yamaguchi J, Kato Y, Rockenbach Y, Natsume A, Todo T
• Inhibition of D-2HG leads to upregulation of a proinflammatory gene signature in a novel HLA-A2/HLA-DR1 transgenic mouse model of IDH1R132H-expressing glioma.
  Journal for immunotherapy of cancer 2022 Chuntova P, Yamamichi A, Chen T, Narayanaswamy R, Ronseaux S, Hudson C, Tron AE, Hyer ML, Montoya M, Mende AL, Nejo T, Downey KM, Diebold D, Lu M, Nicolay B, Okada H
• Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice.
  Neuro-oncology 2022 Chuntova P, Hou Y, Naka R, Yamamichi A, Chen T, Goretsky Y, Hatae R, Nejo T, Kohanbash G, Mende AL, Montoya M, Downey KM, Diebold D, Skinner J, Liang HE, Schwer B, Okada H
• Reliability of IDH1-R132H and ATRX and/or p53 immunohistochemistry for molecular subclassification of Grade 2/3 gliomas.
  Brain tumor pathology 2021 Nishikawa T, Watanabe R, Kitano Y, Yamamichi A, Motomura K, Ohka F, Aoki K, Hirano M, Kato A, Yamaguchi J, Maeda S, Kibe Y, Saito R, Wakabayashi T, Kato Y, Sato S, Ogino T, Natsume A, Ito I
• Tumor antigens in glioma.
  Seminars in immunology 2020 Nejo T, Yamamichi A, Almeida ND, Goretsky YE, Okada H
• Pathogenic Epigenetic Consequences of Genetic Alterations in IDH-Wild-Type Diffuse Astrocytic Gliomas.
  Cancer research 2019 Ohka F, Shinjo K, Deguchi S, Matsui Y, Okuno Y, Katsushima K, Suzuki M, Kato A, Ogiso N, Yamamichi A, Aoki K, Suzuki H, Sato S, Arul Rayan N, Prabhakar S, Göke J, Shimamura T, Maruyama R, Takahashi S,…
• Aberrant Active cis-Regulatory Elements Associated with Downregulation of RET Finger Protein Overcome Chemoresistance in Glioblastoma.
  Cell reports 2019 Ranjit M, Hirano M, Aoki K, Okuno Y, Ohka F, Yamamichi A, Kato A, Maeda S, Motomura K, Matsuo K, Enomoto A, Ino Y, Todo T, Takahashi M, Wakabayashi T, Kato T, Natsume A
• Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion.
  Brain tumor pathology 2018 Yamamichi A, Ohka F, Aoki K, Suzuki H, Kato A, Hirano M, Motomura K, Tanahashi K, Chalise L, Maeda S, Wakabayashi T, Kato Y, Natsume A
• A novel high-sensitivity assay to detect a small fraction of mutant IDH1 using droplet digital PCR.
  Brain tumor pathology 2018 Hirano M, Ohka F, Maeda S, Chalise L, Yamamichi A, Aoki K, Kato A, Tanahashi K, Motomura K, Nishimura Y, Hara M, Shinjo K, Kondo Y, Wakabayashi T, Natsume A
• Remote ischemic preconditioning protects human neural stem cells from oxidative stress.
  Apoptosis : an international journal on programmed cell death 2017 Motomura A, Shimizu M, Kato A, Motomura K, Yamamichi A, Koyama H, Ohka F, Nishikawa T, Nishimura Y, Hara M, Fukuda T, Bando Y, Nishimura T, Wakabayashi T, Natsume A
• A novel all-in-one intraoperative genotyping system for IDH1-mutant glioma.
  Brain tumor pathology 2017 Ohka F, Yamamichi A, Kurimoto M, Motomura K, Tanahashi K, Suzuki H, Aoki K, Deguchi S, Chalise L, Hirano M, Kato A, Nishimura Y, Hara M, Kato Y, Wakabayashi T, Natsume A
• Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities.
  Immunotherapy 2016 Kuramitsu S, Yamamichi A, Ohka F, Motomura K, Hara M, Natsume A
• An immuno-wall microdevice exhibits rapid and sensitive detection of IDH1-R132H mutation specific to grade II and III gliomas.
  Science and technology of advanced materials 2016 Yamamichi A, Kasama T, Ohka F, Suzuki H, Kato A, Motomura K, Hirano M, Ranjit M, Chalise L, Kurimoto M, Kondo G, Aoki K, Kaji N, Tokeshi M, Matsubara T, Senga T, Kaneko MK, Suzuki H, Hara M, …
• CAR T Cells Targeting Podoplanin Reduce Orthotopic Glioblastomas in Mouse Brains.
  Cancer immunology research 2016 Shiina S, Ohno M, Ohka F, Kuramitsu S, Yamamichi A, Kato A, Motomura K, Tanahashi K, Yamamoto T, Watanabe R, Ito I, Senga T, Hamaguchi M, Wakabayashi T, Kaneko MK, Kato Y, Chandramohan V, Bigner DD, …
• Rapid sensitive analysis of IDH1 mutation in lower-grade gliomas by automated genetic typing involving a quenching probe.
  Cancer investigation 2015 Kurimoto M, Suzuki H, Aoki K, Ohka F, Kondo G, Motomura K, Iijima K, Yamamichi A, Ranjit M, Wakabayashi T, Kimura S, Natsume A